Director: Amy Seybert, PharmD
The PGY2 residency in critical care is designed to transition PGY1 resident graduates from generalist practice to specialized practice that meets the needs of critically ill patients. It is defined as an organized, directed, accredited program that builds upon the competencies of postgraduate year one of pharmacy training. This residency is focused in critical care pharmacotherapy, clinical research, and academia and is meant to increase the resident's knowledge, skills, attitudes, and abilities to raise the resident's level of expertise in medication therapy management and clinical and academic leadership
• Serve as an authoritative expert on the optimal use of medications used in the care of patients with critical illness
• Optimize the outcomes of patients with acute and chronic diseases in various settings through the expert provision of evidence-based, patient-centered medication therapy as an integral part of an interdisciplinary team.
• Demonstrate leadership and practice management skills
• Manage and improve the medication-use process for patients with critical illness
• Contribute to the body of critical care pharmacotherapy knowledge
• Demonstrate excellence in the provision of training and educational activities for health care professionals, health care professionals in training, and the public.
• Participate in the management of medical emergencies
• Demonstrate skills required to function in an academic setting
• Conduct outcomes research
• Demonstrate additional skills for managing and improving the medication-use process for patients with critical illness
• Demonstrate additional skills for serving as an authoritative resource on the optimal use of medications used in the care of critical care patients
• Demonstrate additional training and educational skills
Residents come to the University of Pittsburgh School of Pharmacy programs from far and wide, representing more than 25 US States and foreign countries. All residents must be eligible for pharmacist licensure in the Commonwealth of Pennsylvania. Applications for Pharmacist License and Intern Registration are available.
Pennsylvania requires 1500 registered intern hours in order to be eligible for licensure. Of the 1500 hours, only 750 hours can be obtained through an academic program. That is, 750 intern hours must be obtained outside of school. These 750 intern hours must be registered with a state board of pharmacy to count toward licensure in Pennsylvania. If you have not yet started registering hours with your state board of pharmacy, we encourage you to do so as soon as possible in order to be eligible for Pennsylvania licensure. We also encourage you to review your own state's rules regarding the registration, reporting and transfer of intern hours. Please do not hesitate to discuss any questions you have regarding licensure with individual program directors.
Eligible candidates will have completed an ASHP accredited PGY1 pharmacy residency program and must submit the standard application requirements via PhORCAS by December 31st. An on-site interview is required.
To prepare pharmacists to assume any of the following roles:
• Critical care medicine pharmaceutical care provider
• Clinical Educator
• Clinical Researcher
Our residency graduates exit equipped to be fully integrated members of the interdisciplinary cardiovascular team, able to make complex pharmacotherapy recommendations in this fast-paced environment. Training focuses on developing resident capability to deal with range of diseases and disorders that occur in the cardiovascular population.
Graduates are experienced in short-term research in critical care environment and excel in their ability to teach other health professionals and those in training to be health professionals. They also acquire the experience necessary to exercise leadership for this focus in the health system. A strength of our program and a significant focus is on academic pharmacy practice.
Rea RS*, Ansani NT, Seybert AL. Role of inhaled nitric oxide in adult heart or lung transplant recipients. Ann Pharmacother 2005, 39:913-7.
Rea RS*, Kane-Gill SL, Rudis MI, Seybert AL, Oyen LJ, Ou NN, Stauss JL, Kirisci L, Idrees U, Henderson SO. Intravenous amiodarone for the treatment of in-hospital cardiac arrest due to pulseless ventricular tachycardia/ventricular fibrillation (AMVENT Trial). Crit Care Med 2006, 34(6):1617-1623
Bellamy CJ*, Kane-Gill SL, Falcione BA, Seybert AL. Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. J Trauma, 2009;66:954-958.
Smithburger PL*, Kane-Gill SL, Nestor BL*, Seybert AL. Recent Advances and Opinion of the Treatment of Hypertensive Emergencies. Crit Care Nurse 2010. (In Press)
Smithburger PL*, Kane-Gill SL, Seybert AL. Significance of Drug-Drug Interactions in Cardiac Intensive Care Units. Drug Safety (Accepted)
Ford DG*, Seybert AL, Smithburger PL*, Kobulinsky LR, Samosky JT, Kane-Gill SL. Clinical Impact of Simulation-Based Learning Compared to Traditional Didactic Lecturing on Medication Administration Error Rates in Critically Ill Patients. Intens Care Med, March 19, 2010. DOI 10.1007/s00134-010-1860-2
Smithburger PL, Seybert AL, Armahizer MJ*, Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. Expert Opin Drug Saf, 2010;9(5):1-14.
Gokhman R*, Smithburger PL*, Kane-Gill SL, Seybert AL. Pharmacokinetic rationale for combination therapy of pulmonary arterial hypertension. Journal of Cardiovascular Pharmacology. 2010 (accepted)
Smithburger PL*, Kane-Gill SL, Benedict N, Falcione BA, Seybert AL. Grading the severity of drug-drug interactions in the intensive care unit: A comparison between a severity assessment instrument and database severity ratings. Annals of Pharmacotherapy 2010 (accepted)
2008 Residency Preceptor of the Year-Amy Seybert
University of Pittsburgh School of Pharmacy
2009 Pharmacy Residency Excellence Preceptor Award-Amy Seybert
ASHP Research and Education Foundation